Combinatorial Chemistry's Challenge
This article was originally published in Start Up
Executive Summary
As large companies integrate combinatorial chemistry skills, small companies try to maintain their {raison d'être} with smaller "smarter" libraries, novel chemistries and informatics capabilities. They're also trying to build proprietary positions with drug leads of their own through 50-50 deals.
You may also be interested in...
Wanted: Drug Hunters
The process of hunting for drugs is now markedly different than it was a few decades ago, partly because research organizations are much bigger and market pressures more intense. Technology has catalyzed the biggest shifts, decreasing the role of individuals and putting more emphasis on method than conceptualization. But the high-tech methods haven't been as productive as expected, and so research executives are increasingly considering which of the traditional ways might be worth recapturing.
Commercializing Rare Disease Therapies Is Getting Tougher
For an industry increasingly dominated by these drugs, commercial programs need to take on the risk once reserved for development.
Paying for Pharmaceutical Value: The Problem of a One-Size-Fits-All Definition
It is a world, at least the US corner of it, in which any common understanding of drug value is confused by opposing incentives – to opacity and transparency, to looking at benefit broadly or narrowly, long-term or short-term: value, in short, to whom?